The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).
 
Bertrand F. Tombal
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Janssen
Research Funding - Ferring (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Yohann Loriot
Honoraria - Astellas Oncology; Bayer; Medivation/Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Medivation/Pfizer
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen-Cilag; Pfizer
 
Sandrine Marreaud
No Relationships to Disclose
 
Laurence Collette
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - Active Biotech (Inst); Active Biotech (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); Bayer; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Curevac (Inst); Dendreon; Ferring (Inst); Ferring (Inst); Innocrin Pharma (Inst); Janssen (Inst); Janssen-Cilag; MaxiVax ; Millennium; Novartis (Inst); Orion; Roche (Inst); Sanofi; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - Diverse Companies
Other Relationship - ESSA; Nektar; ProteoMediX